NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

177-LUTETIUM-PSMA-617:到2030年考慮新藥和市場預測

177-LUTETIUM-PSMA-617- Emerging Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 959705
出版日期 按訂單生產 內容資訊 英文 50 Pages
商品交期: 10個工作天內
價格
177-LUTETIUM-PSMA-617:到2030年考慮新藥和市場預測 177-LUTETIUM-PSMA-617- Emerging Drug Insight and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 50 Pages
簡介

177-LUTETIUM-PSMA-617是用於治療前列腺癌的放射性藥物。它是放射性核(放射性同位素)177和□PSMA-617的組合,是一種新的癌症治療方法,稱為Seranostics,是一種治療藥物。

本報告調查了177-LUTETIUM-PSMA-617在美國,德國,法國,意大利,西班牙,英國和日本的七個主要國家的市場,並顯示了2030年的前景。提供有關概述,市場評級,SWOT分析,競爭對手概況和其他新方法的信息。

調查範圍

  • 全面的產品概述,包括產品描述,作用機理,劑量和給藥方法,研發活動
  • 開發活動的詳細信息,例如法規批准程序的里程碑
  • 美國,歐洲和日本的藥物研發細節
  • 177-LUTETIUM-PSMA-617專利信息,包括到期日期
  • 到2030年177-LUTETIUM-PSMA-617的銷售預測
  • 開發後期有關新治療劑的全面信息(第三階段)
  • 分析師的考慮和SWOT分析

報告重點

  • 將來,由於正在進行的研發和全球醫療費用的增加,前列腺癌藥物的市場格局將發生巨大變化,並且由於市場的擴大,預計會有更多的製藥公司進入該市場。
  • 公司和研究人員正在尋找機會來增加177-LUTETIUM-PSMA-617的優勢。目前正在開發的治療方法集中於治療/改善疾病的新方法。
  • 177-LUTETIUM-PSMA-617具有新的競爭產品,將在不久的將來對市場產生重大影響。

本報告解決的主要問題

  • 哪個公司在開發177-LUTETIUM-PSMA-617?
  • 177-LUTETIUM-PSMA-617的開發中使用了什麼技術?
  • 177-LUTETIUM-PSMA-617的產品類型,給藥途徑和作用機理是什麼?
  • 臨床試驗的狀態和完成日期是什麼時候?
  • 與177-LUTETIUM-PSMA-617的開發相關的主要合作,合併,收購,許可等是什麼?
  • 177-LUTETIUM-PSMA-617的主要名稱是什麼?
  • 177-LUTETIUM-PSMA-617的預測市場前景如何?
  • 到目前為止,177-LUTETIUM-PSMA-617的歷史是什麼?
  • 您對美國,德國,法國,意大利,西班牙,英國和日本的177-LUTETIUM-PSMA-617的銷售預測如何?
  • 還有哪些其他新產品可用?您如何與這些產品競爭?
  • 在開發後期,目前有哪些新的治療劑?

目錄

第1章藥物概述

  • 產品詳細信息
  • 作用機理
  • 藥物和管理
  • 研發活動
    • 臨床發展
    • 安全性和有效性
  • 其他發展活動

第2章市場評估

  • 7個主要國家的市場分析
  • 美國市場
  • 德國市場
  • 法國市場
  • 意大利市場
  • 西班牙市場
  • 英國市場
  • 日本市場

第3章SWOT分析

第4章分析師的觀點

第5章市場競爭

第6章其他新補救措施

第7章附錄

第8章報表購買選項

目錄
Product Code: DIDM0056

"177-LUTETIUM-PSMA-617- Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Prostate cancer in 7 Major Markets. A detailed picture of the 177-LUTETIUM-PSMA-617 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

Lu-PSMA is an experimental drug, a type known as a radiopharmaceutical. The 177lutetium is a radionuclide (radioactive isotope) (the warhead), while the PSMA-617 is a peptide delivering the warhead to cancer cells (the missile). Lu-PSMA is part of an emerging field of cancer therapy known as theranostics, not the easiest word to get your mind around, but one that you are going to hear a lot more about in the coming years. Lu-PSMA is injected intravenously. The purpose is to deliver radioactivity directly to all prostate cancer cells in the body in men with late-stage, metastatic prostate cancer, something that is not possible with externally delivered radiation which needs to be focused just on small areas of the body. Lu-PSMA targets a protein displayed on the surface of prostate cancer cells known as prostate-specific membrane antigen (PSMA). The PSMA-617 part of the drug seeks out this protein. The 177lutetium part of the drug delivers the damage which hopefully slows down or even kills the cancer cell. About 90% of men express PSMA and are suitable for Lu-PSMA treatment.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around 177-LUTETIUM-PSMA-617.
  • The report contains forecasted sales for 177-LUTETIUM-PSMA-617 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Prostate cancer.
  • The report also features the SWOT analysis with analyst insights and key findings of 177-LUTETIUM-PSMA-617.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

177-LUTETIUM-PSMA-617 Analytical Perspective by DelveInsight

  • In-depth 177-LUTETIUM-PSMA-617 Market Assessment

This report provides a detailed market assessment of 177-LUTETIUM-PSMA-617 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • 177-LUTETIUM-PSMA-617 Clinical Assessment

The report provides the clinical trials information of 177-LUTETIUM-PSMA-617 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Prostate cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence 177-LUTETIUM-PSMA-617 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Prostate cancer are giving market competition to 177-LUTETIUM-PSMA-617 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of 177-LUTETIUM-PSMA-617.
  • Our in-depth analysis of the forecasted sales data of 177-LUTETIUM-PSMA-617 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the 177-LUTETIUM-PSMA-617.

Key Questions:

  • Which company is developing 177-LUTETIUM-PSMA-617 along with the phase of the clinical study?
  • What is the technology utilized in the development of 177-LUTETIUM-PSMA-617?
  • What is the product type, route of administration and mechanism of action of 177-LUTETIUM-PSMA-617?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the 177-LUTETIUM-PSMA-617 development?
  • What are the key designations that have been granted to 177-LUTETIUM-PSMA-617?
  • What is the forecasted market scenario of 177-LUTETIUM-PSMA-617?
  • What is the history of 177-LUTETIUM-PSMA-617 and what is its future?
  • What is the forecasted sales of 177-LUTETIUM-PSMA-617 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to 177-LUTETIUM-PSMA-617?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1 177-LUTETIUM-PSMA-617, Description
  • Table 2 177-LUTETIUM-PSMA-617, Clinical Trial Description
  • Table 3 177-LUTETIUM-PSMA-617, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of 177-LUTETIUM-PSMA-617
  • Figure 2 Patent Details, 177-LUTETIUM-PSMA-617
  • Figure 3 177-LUTETIUM-PSMA-617, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 177-LUTETIUM-PSMA-617, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 177-LUTETIUM-PSMA-617, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 177-LUTETIUM-PSMA-617, Japan Market Size from 2020 to 2030 (in Millions USD)